GMMG-HD10 / DSMM-XX / 64007957MMY2003, MajesTEC-5

Launched by UNIVERSITY OF HEIDELBERG MEDICAL CENTER · Jan 19, 2023

Keywords

ClinConnect Summary

This clinical trial, called GMMG-HD10 / DSMM-XX, is studying new treatment options for patients with multiple myeloma, a type of blood cancer. Specifically, researchers are looking at the safety and effectiveness of two combination therapies that include drugs called teclistamab and talquetamab. The trial is open to adults aged 18 to 70 who have recently been diagnosed with multiple myeloma and are eligible for a transplant. Participants need to have measurable disease and meet certain health criteria to join.

If you or a loved one participates in this trial, you can expect to receive one of the treatment regimens over an extended period. During the study, healthcare providers will closely monitor participants for side effects and how well the treatment works. It’s important to note that there are specific guidelines about who can join, including not having certain health conditions or previous treatments that could interfere with the study. Overall, this trial aims to find better ways to manage multiple myeloma and improve outcomes for patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • - 18 years of age to 70 years of age, inclusive
• • Have an ECOG performance status score of 0 to 2 at screening
• • Have clinical laboratory values meeting prespecified criteria during the Screening Phase.
• Participants in Arms A, A1, B, D, E, E1, F and F1 must also satisfy all of the following criteria to be enrolled in the study:
• 1. Documented multiple myeloma requiring treatment as defined by the criteria below:
• • 1. Multiple myeloma diagnosis according to the IMWG diagnostic criteria
• 2. Measurable disease at screening as defined by any of the following:
• • 1. Serum M-protein level ≥1.0 g/dL or
• • 2. Urine M-protein level ≥200 mg/24 hours or
• • 3. Serum immunoglobulin free light chain level ≥10 mg/dL and abnormal serum free light chain ratio
• • 2. Newly diagnosed participants for whom HDT and ASCT is part of the intended treatment plan (except Arm D participants).
• Participants Arm C and C2 must also satisfy all of the following criteria:
• • 1. Newly diagnosed multiple myeloma according to IMWG criteria.
• • 2. Must have received 4 to 6 cycles of 3 or 4 drug-induction therapy that includes a proteasome inhibitor and/or an IMiD with or without anti-CD38 monoclonal antibody and a single or tandem ASCT. Post-ASCT consolidation is permitted for up to 2 cycles as long as the total number of induction plus consolidation cycles does not exceed 6.
• • 3 Must have received only one line of therapy and achieved at least a PR as per IMWG 2016 without evidence of progression at the time of enrollment.
• • 4. Must have received HDT and ASCT within 12 months of the start of induction therapy and be within 6 months of the last ASCT (7 months for participants who received consolidation) at the time of enrollment.
• Exclusion Criteria:
• • - CNS involvement or clinical signs of meningeal involvement of multiple myeloma.
• • Stroke or seizure within 6 months prior study start Cycle1 Day1.
• • History of transplantations requiring immunosuppressive therapy.
• • Seropositive for HIV, HEP B, Active Hep C infection (details see protocol).
• • COPD with a FEV1 \<50% of predicted normal.
• • Moderate /severe persistent asthma within the past 2 years or any uncontrolled asthma. Exclude if FEV1 \<50% of predicted normal.
• • Concurrent medical or psychiatric condition or disease that is likely to interfere with study procedures, or that in the investigators opinion would constitute a hazard for participants.
• • Contraindications or life-threatening allergies, hypersensitivity, or intolerance to any study drug/excipients.
• • Pregnant, breastfeeding, or planning to become pregnant while enrolled in this study or within 6 months after the last dose of any study treatment regimen.
• • Plans to father a child while enrolled in this study or within 100 days after the last dose of any component of the study treatment regimen.
• • Arm A, A1, B, D, E, E1, F, F1
• • - Prior or current systemic therapy or stem cell transplant for any plasma cell dyscrasia, with the exception of emergency use of a short course (equivalent of dexamethasone 40 mg/day for a maximum 4 days) of corticosteroids before treatment.
• • - Arm B only: Peripheral neuropathy or neuropathic pain Grade 2 or higher as defined by the NCI-CTCAE Version 5.
• • Due to a potential interaction with bortezomib, received a strong CYP3A4 inducer within 5 half-lives prior to enrollment
• • Arm C and C2
• • - Discontinued treatment due to any AE related to lenalidomide as determined by the investigator.
• • - Progressed on multiple myeloma therapy at any time prior to screening.
• • Received a cumulative dose of corticosteroids equivalent to ≥40 mg of dexamethasone within the 14 day period before the start of study treatment administration.
• • Intolerant to the starting dose of lenalidomide (10 mg).
• • For further details on inclusion/exclusion criteria please refer to the study protocol.